To determine the error in the parameter, repeatability assessments were performed in the images taken on the same follow-up on the same animal. correlation (r?=?0.988, p? ?0.001) with ICGA, with no significant difference between the two treatment groups (p?=?0.795). It was also shown that OCTA provided good repeatability outcomes of the quantitative measurements. Using Bland-Altman plots, vessel growth density Diclofensine hydrochloride values between anti-VEGF treatments were compared to control saline group. It was observed that aflibercept provided longer lasting effect than ranibizumab. We also observed that in both drugs, the topical route of administration topical provided longer regression outcomes compared to one-time sub-conjunctival injection. Thereby, with this pilot study, it was exhibited that OCTA is usually a reliable imaging technique to follow-up and monitor corneal vascularisation and its treatment quantitatively. Diclofensine hydrochloride strong class=”kwd-title” Subject terms: Drug delivery, Diagnostic markers, Experimental models of disease, Preclinical research, Translational research Introduction A wide variety of insults to the cornea, ranging from chemical injuries to microbial keratitis can disrupt the corneal vascularity and affect corneal clarity leading to visual impairment1. Abnormal corneal angiogenesis, may lead to corneal opacification, which is one of the most common causes of irreversible visual impairment worldwide2. Treatment options that have been described include topical corticosteroid3, non-steroid anti-inflammatory medications4, cyclosporine5, photodynamic therapy6, laser photocoagulation7 and fine needle diathermy8. However, none of these options target the molecular mediators of angiogenesis and may provide limited clinical efficiency or undesirable side-effects9. Anti-vascular endothelial growth factor (anti-VEGF) therapies are effective and well-tolerated medications that have revolutionized the treatment of retinal conditions such as neo-vascular age-related macular degeneration and macular oedema in diabetic retinopathy or retinal vein occlusions10. The therapy is now Diclofensine hydrochloride considered standard of care in clinical practice for conditions where there is usually abnormal vasculature in the retina and choroid11. Fgfr1 Anti-VEGF antibodies are recently being investigated as new promising therapies for corneal vascularization as they suppress angiogenesis by direct VEGF inhibition12. The most commonly used drugs in corneal applications have been bevacizumab and ranibizumab. Ranibizumab has been shown to provide better penetration, through the corneal epithelial barrier, than larger biologic brokers such as bevacizumab and thus reaching higher therapeutic concentrations in the stroma13. From the literature, it is suggested that ranibizumab may be modestly superior to bevacizumab in the treatment of corneal neovascularisation in terms of both on-set of action and degree of efficacy, although direct comparisons have failed to show a clear benefit14. Aflibercept, anti-VEGF antibody, has also been recently used for corneal neovascularization, and provides higher binding affinity of VEGF by also interacting with platelet-derived growth factor (PDGF)13,14,. The tighter binding of the anti-VEGF to the native receptor, contributes it to a longer half-life compared to other anti-VEGFs, that allows for extended Diclofensine hydrochloride dosing intervals15,16. Although there have been a few studies comparing the efficacy of topical and sub-conjunctival anti-VEGF route administration for the treatment of corneal vascularisation, direct comparisons between ranibizumab and aflibercept are lacking17,18. Moreover, reliable and objective tools for the imaging of corneal vascularization treatment have not been studied for anti-VEGF therapies. Robust quantitative diagnostic evaluations are of necessity in clinical translational research. Therefore, in order to determine the true superiority of the modes of administration in different drugs, one-to-one comparison studies using quantitative tools need to be evaluated. We have previously described the use of ASOCTA (anterior segment optical coherence tomography angiography) as a quantitative diagnostic tool for corneal vascularization in a rabbit model, where we compared it to ICGA and slit lamp bio-microscopy, demonstrating good repeatability and better vessel delineation than other conventional techniques12. We have also shown that ASOCTA allows quantitative monitoring of vascularized area after antiangiogenic treatment in human subjects12. Potential clinical application of the ASOCTA and its advantages in monitoring new vessel development in three dimensions using en-face segmentation has been previously described19. However, in order to effectively understand the treatment and its response to corneal vascularization, objective imaging.